| Field | Specification |
|---|---|
| Target | |
| Alternative names | Moesin; Membrane-organizing extension spike protein; MSN |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human Moesin/MSN recombinant protein (Position: R184-K568). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 8D4 is a mouse monoclonal antibody that recognizes moesin (gene MSN) in human, mouse, rat and monkey samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 67.8 kDa, and the supplier reports an observed band at about 78 kDa.
Moesin (MSN) is a member of the ezrin-radixin-moesin (ERM) family that links actin filaments to proteins in the plasma membrane. It becomes active when a C-terminal threonine is phosphorylated, and it helps shape the cell cortex in processes such as cell migration, adhesion and lymphocyte polarization.
| Target | Moesin (gene MSN; UniProt P26038, human) |
|---|---|
| Clone | 8D4 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG1 |
| Reactivity | Human, Mouse, Rat, Monkey |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 67.8 kDa |
| Observed MW | 78 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat, Monkey) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1x6 cells (Human) |
Samples with a confirmed band (WB): human HL-60 cells, human K562 cells, monkey COS-7 cells, rat kidney tissue, mouse kidney tissue, human MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human gastric adenocarcinoma tissue, human colonic adenocarcinoma tissue, human liver cancer tissue, human placenta tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SiHa cells.
Samples with a confirmed signal (flow cytometry): U87 cells.
Immunogen
Recombinant human Moesin/MSN fragment (Arg184–Lys568), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse, rat and monkey. UniProt places moesin in the cell membrane, cytoplasm and apical cell membrane. Tissue expression noted by UniProt (human): In all tissues and cultured cells studied. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
